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Cohorts included in the discovery meta-analysis 
In total, 480,982 (10,257 cases and 470,725 controls) Caucasians of European ancestry (from 
Iceland, Denmark, the UK, Netherlands, and the US) were recruited for the study (Figure 1). 
The Icelandic dataset comprised individuals who responded to a media inquiry for those with 
RLS-like symptoms and subjects that participated in various studies at deCODE Genetics 
and who had answered a screening questionnaire. RLS was assessed by using a self-
completed questionnaire based on the International RLS Study Group diagnostic criteria1 
(IRLSSG). All participating individuals who donated blood provided written informed 
consent. All sample identifiers were encrypted in accordance with the regulations of the 
Icelandic Data Protection Authority. Approval for the study was provided by the National 
Bioethics Committee of Iceland.  
Both the DBDS and the INTERVAL subjects were recruited from blood banks in Denmark 
and in the UK, respectively. RLS status among the blood donors was assessed using the 
Cambridge-Hopkins RLS questionnaire (CH-RLSq), which is a 10-item questionnaire with 
excellent diagnostic specificity (94%) and sensitivity (87.2%), albeit somewhat inflated due 
to their being derived from a specialized blood donor cohort validated against telephone 
interview versus face-to-face clinical impression and informed by PLM determinations in a 
general population 2. Definite and probable RLS cases were combined into one group and 
the remaining participants were included in analyses as controls. All DBDS participants 
provided written informed consent. The DBDS dataset was approved by The Scientific 
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Ethical Committee of Central Denmark (M-20090237) and by the Danish Data Protection 
agency (30-0444). GWAS studies in DBDS were approved by the National Ethical 
Committee (NVK-1700407). The INTERVAL dataset was approved by the National 
Research Ethics Service Committee East of England - Cambridge East (Research Ethics 
Committee (REC: 11/EE/0538). Written informed consent was collected from all 
INTERVAL participants.  
For UK Biobank participants, the clinical diagnostic code International Classification of 
Diseases, tenth revision: G25.8 (ICD10) was used to inform about case status of restless leg 
syndrome. The specific sub-code for RLS (G25.81) was not available. UK Biobank is 
approved by the North West Multi-centre Research Ethics Committee, and by the Patient 
Information advisory Group, the National Information Governance Board for Health and 
Social Care, and from the Community Health Index Advisory Group. UK Biobank also holds 
a Human Tissue Authority license. 
Furthermore, we included a dataset from the Program in Sleep at Emory University, which 
is a tertiary care center for RLS that is recognized as a Quality Care Center for RLS by the 
RLS Foundation. RLS affectation status in this dataset was limited to adults of Northern 
European origin (i.e., African Americans, Hispanics and Asians were excluded). RLS status 
was assessed by one of two clinicians familiar with RLS (David B. Rye and Lynn Marie 
Trotti) complemented by objective measurements of periodic leg movements in sleep 
(PLMS) and additional secondary and supportive diagnostic features1. Thus, RLS status was 
clinically verified. An institutional review board at Emory University, Atlanta, Georgia, US, 
approved the study protocol (HIC ID 133-98). All participants provided written informed 
Supplementary materials for the paper entitled Large genome-wide-association study identifies three novel risk 
variants for restless legs syndrome  
 
Page 6 of 34 
 
consent. The Donor InSight-III (DIS-III, 2015-2016) is the second follow-up of an 
observational cohort study conducted among blood and plasma donors in the Netherlands 
aimed to gain insight into characteristics, health and behavior of donors3. RLS status was 
self-reported using the questionnaire developed as part of the RISE study4. The questionnaire 
is based on the IRLSSG criteria and it was developed by REDS investigators in collaboration 
with an expert on RLS (Professor David B. Rye)4. The Medical Ethical Committee of the 
Academic Medical Center (AMC) in the Netherlands, and Sanquin’s Ethical Advisory Board 
approved DIS-III and all participants gave their written informed consent.     
The effect estimates for the 20 known RLS-associated variants5 were largely similar to the 
effect estimates observed in each of the cohorts included in this meta-analysis 
(Supplementary Table 2). This indicates that the phenotypes in each cohort are comparable 
to previous RLS GWAS efforts. Moreover, the meta-analysis of the discovery and follow-up 
samples replicated 19 of the 20 previously reported variants. 
Questionnaires used to assess RLS 
IRLSG RLS diagnostic 
criteria1 
CH-RLSq2 
Questionnaire used by the 
InSight-III cohort4 
1. An urge to move the legs 
usually but not always 
accompanied by or felt to be 
caused by uncomfortable and 
unpleasant sensations in the legs 
Do you have, or have you had, 
recurrent uncomfortable feelings 
or sensations in your legs while 
you are sitting or lying down? 
a) Yes 
b) No 
When you try to relax in the 
evening or sleep at night, how 
often do you have unpleasant, 
restless feelings in your legs that 
can be relieved by walking or 
movement? 
a) Never 
b) Rarely (2 to 4 times a 
month) 
c) Often (5 to 15 times a 
month) 
d) Very often (16 or more 
times a month) 
2. The urge to move the legs and 
any accompanying unpleasant 
Do you, or have you had, a 
recurrent need or urge to move 
How often do you experience a 
strong urge to move your legs 
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sensations begin or worsen 
during periods of rest or 
inactivity such as lying down or 
sitting. 
your legs while you were sitting 
or lying down?  
a) Yes 
b) No 
usually accompanied or caused 
by unpleasant sensations in your 
legs – for example restlessness, 
creepy-crawly, or tingly feelings? 
a) Never 
b) Rarely (2 to 4 times a 
month) 
c) Often (5 to 15 times a 
month) 
d) Very often (16 or more 
times a month) 
3. The urge to move the legs and 
any accompanying unpleasant 
sensations are partially or totally 
relieved by movement, such as 
walking or stretching, at least as 
long as the activity continues.  
If you get up or move around 
when you have these feelings do 
these feelings get any better while 
you actually keep moving? 
a) Yes 
b) No  
c) Don’t know 
Is the urge to move your legs or 
are the unpleasant sensations 
partially or totally relieved by 




c) Don’t know 
4. The urge to move the legs and 
any accompanying unpleasant 
sensations during rest or 
inactivity only occur or are worse 
in the evening or night than 
during the day. 
Are you more likely to have these 
feelings when you are resting 
(either sitting or lying down) or 
when you are physically active? 
a) Resting 
b) Active 
Does the urge to move your legs 
begin, or do the unpleasant 
sensations begin or worsen, 
during periods of rest or 




c) Don’t know 
5. The occurrence of the above 
features are not solely accounted 
for as symptoms primary to 
another medical or a behavioral 
condition (e.g., myalgia, venous 
stasis, leg edema, arthritis, leg 
cramps, positional discomfort, 
habitual foot tapping).  
Which times of day are these 
feelings in your legs most likely 
to occur?  
a) Morning  
b) Mid-day  
c) Afternoon  
d) Evening  
e) Night  
f) About equal at all times 
At what times is the urge to move 
your legs or the unpleasant 
sensations most bothersome? 
a) In the morning (before 
noon) 
b) In the afternoon (before 
supper) 
c) In the evening (after 
supper) 
d) At night while sleeping 
e) No difference by time of 
day 
 Will simply changing leg position 
by itself once without continuing 
to move usually relieve these 
feelings?  
a) Usually relieves  
b)  Does not usually relieve  
c) Don’t know 
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 Are these feelings ever due to 
muscle cramps?  
a) Yes  
b) No  
c) Don’t know 
 
 If so, are they always due to 
muscle cramps?  
a) Yes  
b) No  
c) Don’t know 
 
 
Cohorts used for follow-up/replication analysis 
 
After the discovery meta-analysis, the novel markers identified in the discovery meta-
analysis were tested for replication in two cohorts. 
EU-RLS-GENE study 
RLS cases in the EU-RLS-GENE study were recruited in specialized outpatient clinics for 
movement disorders as well as in sleep clinics in eight European countries, French Canada, 
and the United States. RLS diagnosis was based on a face-to-face interview by an expert 
neurologist, implementing the diagnostic criteria established by the IRLSSG in 2003. 
Ancestry-matched controls were obtained for each case sample. A total of 6,228 cases and 
10,992 controls was included in the statistical analysis. Written informed consent was 
obtained from all participants. 
US (RBC-Omics) cohort  
The RBC-Omics cohort included blood donors recruited from four blood centers in the 
United States as a part of the Recipient Epidemiology and Donor Evaluation Study (REDS-
III)6-8. RLS status was assessed using the CH-RLSq as in the DBDS and INTERVAL cohorts. 
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Analysis in the cohort was restricted to ancestry defined Caucasians and included 423 cases 
and 7,334 controls. All subjects provided written informed consent. 
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Genotyping, imputation, and association analysis of cohorts included in the discovery 
meta-analysis 
 
Icelandic dataset  
DNA samples from 150,656 subjects of Icelandic descent were genotyped at deCODE 
genetics, on one or more of 16 different Illumina SNP genotyping-arrays (including 14,084 
subjects as part of this study, 2,636 cases and 11,448 controls). Approximately 34.2 million 
sequence variants identified through whole-genome sequencing (WGS) (with mean 
sequencing depth of 10X, median 32X) of 8,453 Icelanders using Illumina GAIIx and 
HiSeq2000 instruments, were imputed into the 150,656 genotyped Icelanders using the LRP 
algorithm9 which yielded LRP haplotypes having high density SNP information (described 
in detail earlier10).  Association analysis for each marker was done using logistic regression 
accounting for cryptic relatedness and adjusting for sex and year of birth10. 
Danish (The Danish Blood Donor Study) dataset  
DNA samples from 26,565 subjects from DBDS were chip-typed using the Infinitum Global 
Screening Array on Illumina® genotyping platform at deCODE Genetics, Iceland. These 
arrays use ~660,000 common genetic markers which span the entire genome and are 
representative of all major populations to maximize imputation accuracy. Samples and 
variants with less than 98% yield were excluded. These samples were long-range phased 
through Eagle211 by using deCODE’s North West European reference panel. This panel 
includes whole genome sequencing data of 15,576 individuals from Scandinavia, the 
Netherlands and Ireland, 8,429 Danes (1,590 of these are from DBDS). For this reference 
panel, the Graphtyper 12 variant caller was used to call genotypes from whole genome 
sequencing data. The chip-genotyping, whole genome sequencing, quality control, long 
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range phasing, imputation, and association analysis processes were performed at deCODE 
genetics using the methods described in the section above10. 
US (Emory) dataset  
Genotyping was performed at deCODE Genetics, Reykjavik, Iceland, using Illumina Omni 
Express chips. In QC steps, variants were excluded if they (i) had<94% yield, (ii) had<0.1% 
minor allele frequency (MAF), (iii) failed Hardy-Weinberg test (P<1 × 10−6) or (iv) showed 
significant (P<1 × 10−6) difference between genotype batches. Samples with<94% yield were 
excluded. SHAPEIT (v2.790)13 was used to phase the resulting genotypes, followed by 
IMPUTE2 (v2.3.2)14 to impute un-genotyped variants. To study the population structure and 
the ancestry of samples we used the ADMIXTURE (v 1.2)15 and EIGENSOFT (v 6.0.1) 
software16. Samples were excluded if they were identified as ethnic outliers. We used the 
principal component analysis to identify and exclude outliers from the analysis.  Briefly, to 
include samples in the study, we defined recent European ancestry (downloaded from 
http://csg.sph.umich.edu/chaolong/LASER/) as samples that fell into an ellipsoid spanning 
exclusively European population of the HGDP panel. To perform association analysis, we 
used SNPTEST17 where we used frequentist additive method while adjusting for gender, and 
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UK (The INTERVAL Study) dataset  
 
INTERVAL samples were genotyped using the Affymetrix UK Biobank Axiom array. 
Genotype calling was done by applying the Axiom GT1 algorithm (described in detail 
elsewhere18). Individuals who had a call rate <97% were excluded. Individuals were also 
excluded if contamination was indicated (>10% or >3% and >10 close relatives) and if they 
had a sex mismatch, or if they were not of European ancestry (PCA-based scores on PC1 or 
PC2<0). Individuals of non-European ancestry were identified using a set of high-quality 
autosomal variants and defined as variants with MAF>0.05, Hardy-Weinberg equilibrium 
(HWE) p value <5 x 10-6, and r2<0.2 between pairs of variants. In the INTERVAL dataset, 
additional genetic markers were imputed for all autosomes using a two-step procedure. 
IMPUTE3 was applied for phasing of study genotypes in sets of 5000 variants with 250 
variants overlapping between sets. For the imputation of variants, the Sanger Imputation 
Server (https://imputation.sanger.ac.uk) was used. This server implemented the Burrows-
Wheeler transform imputation algorithm PBWT and analyzed whole chromosomes. A 
combined UK10K and the 1000 Genomes Phase 3 reference panel was used (URL, 
https://www.internationalgenome.org/data-portal/data-collection/phase-3). The association 
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The UK (UK Biobank) dataset 
 
Initially, 50,000 UK Biobank samples were genotyped using the Affymetrix UK BiLEVE 
Axiom array. Subsequently, the remaining 450,000 samples were genotyped using 
Affymetrix UK Biobank Axiom® array, which genotyped approximately 850,000 variants. 
There is more than 95% common content in the two arrays20,21. The Wellcome Trust Centre 
for Human Genetics performed imputation using a combination of 1000 Genomes phase 322, 
UK10K23, and HRC21 reference panels, and the association of all QC markers was done at 
deCODE using the pipeline described earlier10. 
 
The Netherlands (Donor InSight-III) dataset 
 
DNA was genotyped in one batch using the UK Biobank – version 2 Axiom Array (Thermo 
Fisher, CA, USA), which contains 820,967 single nucleotide polymorphisms (SNP) and 
insertion/deletion (INDEL) markers24. Sample quality control (QC) by Thermo Fisher 
consisted of dish QC (≥0.82), QC call rate (≥97%) and copy number analyses (MAPD2 value 
≤0.35 and WavinessSD3 value ≤0.1), and resulted in 789,754 markers25-27. Thermo Fisher 
also performed probeset QC with SNP-specific priors from the UK Biobank results using 
default human settings. Further QC was performed according to the UK Biobank protocol 
and comprised of departures from HWE calculated with bcftools, plate effects and sex effects 
taking into account diploid/haploid/sex specific markers. Any marker that failed at least one 
test (p<10-6) was set to missing20. The Sanger imputation pipeline (Eagle phasing and BWT 
imputation using the HRC v1.1 panel) was used to impute SNPs11,23,28. After imputation, 
SNPs with an imputation score R2≤0.3 and minor allele frequency (MAF) ≤0.01 were 
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excluded. Relatedness and ethnic background were checked, and only unrelated Caucasian 
samples were included. Finally, principal components analysis (PCA) was carried out in 






Briefly, we did not perform a joint meta-analysis using complete data from all 
cohorts, instead we used summary statistics data for RLS association from Iceland, UK 
Biobank, UK INTERVAL, Denmark, US Emory, and the Netherlands to run meta-analysis 
using fixed effect model (Mantel-Haenszel). The QC, imputation, and association tests, 
adjusting for principle components were done at cohort level and later meta-analyzed. 
Therefore, we have not done a joint principle component analysis of the discovery cohorts. 
Detailed information about the QC, imputation, and the association method for 
Icelandic 29, UK Biobank 30, UK INTERVAL 30, and Danish (see methods) data used in this 
study have already been described by respective cohorts. For these samples we therefore 
believe that it is not necessary to generate the PCA plots. However, for the US Emory, and 
the Dutch Insight-III cohorts we present information in the methods section including  PC 
plots showing genomic variation between cases and controls (below Supplementary Figure 
10 and Supplementary Figure 11). 
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Genotyping, imputation, and association analysis of cohorts used for follow-
up/replication analysis 
 
EU-RLS-GENE consortium dataset 
 
All samples were genotyped on the Affymetrix Axiom CEU array. Genotyping was 
performed following the manufacturer’s protocol and implementing their best practice 
recommendations. Genotype calling was performed in batches based on genotyping date 
using the Axiom GT1 algorithm.  
Individuals were excluded if they had a call rate < 98%, had incorrect or ambiguous sex calls 
or showed potential sample contamination. In addition, related individuals (PIHAT ≥ 
0.09375) and population outliers (deviation ≥ 4 SD from the population mean in an MDS 
analysis) were removed. SNPs were excluded if they had a call rate < 98%, a MAF < 0.01, 
showed > 1 discordant genotype in duplicate samples, had a P value for deviation from HWE 
(PHWE) ≤ 1 x 10
-5 in controls or failed cluster quality criteria implemented in the Affymetrix 
SNPolisher R package. Imputation in the EU-RLS-GENE consortium GWAS was carried 
out in a two-step procedure. Genotype phasing was performed per chromosome using 
SHAPEIT2 with standard settings, followed by imputation with IMPUTE2 in all samples in 
chunks of 5 Mb with a buffer of 250 kb. SNPs with PHWE ≤ 1 x 10
-5 and an IMPUTE2 info 
score < 0.5 were filtered out prior to any statistical analysis. Finally, the association analysis 
was carried out using methods described elsewhere5. 
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US (RBC-Omics) dataset 
 
The RBC-omics cohort was genotyped with a custom designed Affymetrix Axiom array 
based off the UK Biobank Array, which included probes for ~879,000 SNPs 7. All genotype 
calls and quality control steps were performed with the Affymetrix Power Tools according 
to their best practice workflow. Individuals with <97% call rate or Dish QC (DQC) < 0.85 
were excluded from all subsequent analysis, as were individuals with sex mismatch. 
Genotypes were called using two different batch groupings, and SNPs with inconsistent calls 
in five or more individuals were excluded from analysis. Low and medium confidence called 
SNPs were also excluded, resulting in 831,797 high confidence SNPs. Cryptic relatedness 
among individuals was determined via PLINK identity-by-descent analysis. For pairs of 
individuals having PI_HAT > 0.4 or IBS > 0.9 the member with fewer SNP calls was 
excluded from analysis. Finally, SNPs deviating from HWE (P ≤ 1 × 10−4) were also 
excluded. The resulting 811,784 SNPs for 12,789 individuals were used to perform statistical 
phasing with SHAPEIT and imputation of unmeasured genotypes with IMPUTE2 using a 
cosmopolitan sample of 1000 Genome Project phase 3 for reference haplotypes. Caucasian 
ancestry was determined using STRUCTURE and individuals were compared to 1000 
Genome reference populations. Individuals who self-reported as Caucasian and were >80% 
European Ancestry were used in the analysis. The final high-quality dataset had 8.1 million 
SNPs at 5% MAF and 14 million SNPs at 1% MAF. Alleles at MAF < 1% were excluded. 
Association of the five variants identified in the discovery meta-analysis with RLS, was 
investigated using a multivariate logistic regression model adjusted for sex, age and the first 
10 principal component scores. 
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Supplementary Figure 1: The regional association plots ‘LocusZoom’ for lead variant 
‘rs10188680-T’ association (flanked by ±500KB) with RLS in the discovery meta-analysis. 
Each dot represents its association strength ‘-log10(P)’ with RLS. The color code represents 
‚r2, measure the LD of the lead variant with surrounding variants.   
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Supplementary Figure 2. The regional association plots ‘LocusZoom’ for lead variant 
‘rs10068599-T’ 
 
Supplementary Figure 2: The regional association plots ‘LocusZoom’ for lead variant 
‘rs10068599-T’ association (flanked by ±500KB) with RLS in the discovery meta-analysis. 
Each dot represents its association strength ‘-log10(P)’ with RLS. The color code represents 
‚r2, measure the LD of the lead variant with surrounding variants.   
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Supplementary Figure 3: The regional association plots ‘LocusZoom’ for lead variant 
‘rs112716420-G’ association (flanked by ±500KB) with RLS in the discovery meta-analysis. 
Each dot represents its association strength ‘-log10(P)’ with RLS. The color code represents 
‚r2, measure the LD of the lead variant with surrounding variants.   
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Supplementary Figure 4: The regional association plots ‘LocusZoom’ for lead variant 
‘rs10769894-A’ association (flanked by ±500KB) with RLS in the discovery meta-analysis. 
Each dot represents its association strength ‘-log10(P)’ with RLS. The color code represents 
‚r2, measure the LD of the lead variant with surrounding variants.   
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Supplementary Figure 5. The regional association plots ‘LocusZoom’ for lead variant 
‘rs58127855-T’ 
 
Supplementary Figure 5: The regional association plots ‘LocusZoom’ for lead variant 
‘rs58127855-T’ association (flanked by ±500KB) with RLS in the discovery meta-analysis. 
Each dot represents its association strength ‘-log10(P)’ with RLS. The color code represents 
‚r2, measure the LD of the lead variant with surrounding variants.   
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Supplementary figure 6: Of the 23 RLS variants, we found cis-eQTL data for 11 of the 23 
RLS variants impacting 17 genes. Four variants are significantly associated with cis gene 
expression at least in one tissue tested and are in high linkage disequilibrium (LD) (r2>0.90) 
with the top eQTL variant of each respective gene. These are rs10068599-T lowering the 
expression of RANBP17 in the tissues thyroid, sun exposed skin on lower leg, liver, the left 
ventricle of the heart, and brain tissues in the basal ganglia. Moreover, the rs3784709-T 
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which lowers the expression of SKOR1 and MAP2K5 in tissues pituitary, pancreas, and breast 
mammary tissue. Finally, the rs10653756-CACAG lowering the expression of CASC16 in 
testis. Cis-eQTL effect estimates (normalized) are provided and those sharing same causal 
signal (COJO conditional analysis) with eQTL and are Bonferroni significant (P < 3.3 x 10-
06) are labeled with an asterisk.  
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Genetic risk analyses: UK Biobank  
Analyses where the polygenic risk score for RLS was applied as the exposure variable were 
conducted among individuals included in the UK Biobank cohort. UK Biobank is an open 
access research resource with data on 500,000 UK adults (ages 40 years and up). Genotyping 
was carried out on all participants and several baseline measurements were conducted, 
including a comprehensive self-report health related questionnaire that was administered to 
all included individuals, which among other things contained questions regarding diet, 
cognitive functioning, work history and digestive health. Moreover, the UK Biobank has 
linked to individual level data from hospitals and general practitioners. 
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Supplementary figure 7. The phenotypic variance explained by the RLS polygenic risk 
score (PRS) using different P-parameters from the Linkage Disequilibrium Score 
regression (LDSC) method   
 
Supplementary figure 7: RLS PRS for UKB Biobank participants was constructed using 
GWAS meta-analysis of Iceland, Denmark, US Emory, and the Netherlands. Therein, the 
largest variance (0.97%) is explained by the ‘0.01’ threshold for ICD 10 G25.8 in UK 
Biobank. This PRS was calculated in N = 12,075 independent biological samples and using 
a threshold  of 0.01 it  was further used to perform phenome-wide PRS association analysis 
of RLS PRS in UK Biobank for case-control (disease/phenotypes) and quantitative traits. 
The number of variants included in this RLS-PRS is 600,420.  
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Supplementary Figure 8. ROC curve showing sensitivity and specificity of RLS PRS vs 



















Supplementary Figure 8: ROC curve showing sensitivity and specificity of RLS PRS vs 
corresponding ICD 10-code G25.8 phenotype in the UK Biobank, where A) is for all and B-
E) are for 1st, 2nd, 3rd and 4th quartile respectively. Analyses were done for N = 12,075 
independent biological samples. 
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Supplementary figure 9. QQ-plots for discovery association analysis 
 
Supplementary figure 9: QQ-plot of P values for RLS association results. Expected versus 
observed P values. Therein, we present minor allele frequency (MAF) based split plots, for 
detailed description of observed P distribution versus expected P. 
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Supplementary figure 10. Principal component analysis plot for the Netherlands cohort 
 
 
Supplementary figure 10: Principal component analysis plot for the Netherlands cohort with 
N = 2,363 independent biological samples (565 RLS cases and 1,798 controls). On the x-axis 
is PC1 and on y-axis PC2. Each dot represents participant in the study from Dutch cohort 
where RLS cases are red and controls in green color. The plot shows that most of the variation 
in cases and controls is captured through PC1 & PC2. In the association analysis, to be 
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Supplementary figure 11. Principal component analysis (PCA) plot for US Emory 
cohort 
Supplementary figure 11: Principal component analysis (PCA) plot for US Emory cohort 
with N = 1,417 independent biological sample (696 RLS cases and 721 controls). On the x-
axis A) through D) is PC1, PC2, PC3, and PC4. Whereas on y-axis A) through D) is PC2, 
PC3, PC4, and PC5. Each dot represents the participant in the study from US Emory cohort 
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where RLS cases are colored green and controls in red color. These plots show that most of 
the variation in cases and controls is captured through PC1 – PC5. Furthermore, in the 
association analysis, we used 1st 20 PC to correct for variations arising due to population 
structure. 
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